Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment

Contributed by: PR Newswire

Tags

CALLIDITAS-USPTO

More Like This

Calliditas provides setanaxib patent update

Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®

European Medicines Agency Committee for Orphan Medicinal Products provides positive opinion on Calliditas' application for setanaxib in Alport syndrome

Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome

Calliditas provides patent update

Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis